Positions

Overview

  • Dr. Bashir graduated from the University of the Punjab with a B.Sc. in Anatomy and Physiology, and received his MD from the King Edward Medical College in Pakistan. He received his MPH from the University of Alabama at Birmingham School of Public Health. After completing his internship and post-graduate residency training in combined Internal Medicine and Neurology at the Southern Illinois University School of Medicine, Springfield, Illinois, Dr. Bashir joined the Department of Neurology at the University of Alabama at Birmingham as an Instructor and Fellow. He completed his advanced fellowship training in Neuroimmunology and Multiple Sclerosis under the tutelage of (late) John N. Whitaker, MD. Dr. Bashir is currently a Professor of Neurology and the Director of the Multiple Sclerosis Center at UAB. Dr. Bashir is board certified with the American Board of Psychiatry and Neurology (Neurology), and the American Society for Neuroimaging (MRI/CT). Dr. Bashir has co-authored a “Handbook of Multiple Sclerosis”, in addition to publishing several review articles, abstracts, peer-reviewed scientific papers, and book chapters. He has also served as a Principal Investigator and a Co-Investigator for greater than 30 multi-center clinical trials related to multiple sclerosis. He has been the recipient of grants from the National Multiple Sclerosis Society and the National institutes of Health.
  • Selected Publications

    Academic Article

    Year Title Altmetric
    2018 Phase 2 trial of ibudilast in progressive multiple sclerosisNew England Journal of Medicine.  379:846-855. 2018
    2018 Randomized Trial of Clitoral Vacuum Suction Versus Vibratory Stimulation in Neurogenic Female Orgasmic DysfunctionArchives of Physical Medicine and Rehabilitation.  99:299-305. 2018
    2017 Financial Capacity and its Cognitive Predictors in Progressive Multiple SclerosisArchives of Clinical Neuropsychology.  32:943-950. 2017
    2017 Medical decision-making capacity and its cognitive predictors in progressive MS: Preliminary evidenceJournal of the Neurological Sciences.  380:38-43. 2017
    2016 Design, rationale, and baseline characteristics of the randomized double-blind phase II clinical trial of ibudilast in progressive multiple sclerosisControlled Clinical Trials.  50:166-177. 2016
    2016 Introducing demographic corrections for the 10/36 Spatial Recall TestInternational Journal of Geriatric Psychiatry.  31:406-411. 2016
    2015 Effect of in-painting on cortical thickness measurements in multiple sclerosis: A large cohort studyHuman Brain Mapping.  36:3749-3760. 2015
    2013 Constraint-induced movement therapy for the lower extremities in multiple sclerosis: Case series with 4-year follow-upArchives of Physical Medicine and Rehabilitation.  94:753-760. 2013
    2012 Isolated CNS Whipple disease with normal brain MRI and false-positive CSF 14-3-3 protein: A case report and review of the literatureBrain and Behavior.  2:838-843. 2012
    2012 Examining sleep, fatigue, and daytime sleepiness in pediatric multiple sclerosis patientsMultiple Sclerosis.  18:481-488. 2012
    2011 Challenges in diagnosis of isolated central nervous system vasculitisBrain and Behavior.  1:57-61. 2011
    2008 Constraint-Induced Movement therapy can improve hemiparetic progressive multiple sclerosis. Preliminary findingsMultiple Sclerosis.  14:992-994. 2008
    2007 Glatiramer acetate in primary progressive multiple sclerosis: Results of a multinational, multicenter, double-blind, placebo-controlled trialAnnals of Neurology.  61:14-24. 2007
    2005 A randomized, multicentre, open-label, parallel-group trial of the tolerability of interferon beta-1a (Rebif®) administered by autoinjection or manual injection in relapsing-remitting multiple sclerosisMultiple Sclerosis.  11:585-591. 2005
    2003 Chlamydia pneumoniae and multiple sclerosis: The latest etiologic candidateEpidemiology.  14:133-134. 2003
    2001 Surgery for spinal cord compression in multiple sclerosisCurrent Opinion in Neurology.  14:765-769. 2001
    2000 Surgery for cervical spinal cord compression in patients with multiple sclerosisNeurosurgery.  47:637-643. 2000
    2000 Importance of paraclinical and CSF studies in the diagnosis of MS in patients presenting with partial cervical transverse myelopathy and negative cranial MRIMultiple Sclerosis.  6:312-316. 2000
    1999 Clinical and laboratory features of primary progressive and secondary progressive MSNeurology.  53:765-771. 1999
    1999 Urinary myelin basic protein-like material in patients with multiple sclerosis during interferon beta-1b treatmentArchives of Neurology -Chigago-.  56:687-691. 1999
    1998 Hemianopsia in dementia with Lewy bodiesArchives of Neurology -Chigago-.  55:1132-1135. 1998
    1998 Current immunotherapy in multiple sclerosisImmunology and Cell Biology.  76:55-64. 1998
    1994 Clozapine for the control of hemiballismusClinical Neuropharmacology.  17:477-480. 1994

    Chapter

    Year Title Altmetric
    2012 Acute therapies and disease-modifying therapies for multiple sclerosis.  273-291. 2012
    2011 Plasma exchange and IV immunoglobulin for acute demyelinating relapses.  87-91. 2011

    Research Overview

  • Multiple Sclerosis and related disorders
    Central nervous system demyelinating disorders
    Clinical trial design
  • Principal Investigator On

  • Private Grant  awarded by ABBVIE INC 2019 - 2024
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION 2014 - 2023
  • Private Grant  awarded by ACTELION CLINICAL RESEARCH, INC. 2017 - 2021
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION 2016 - 2020
  • Private Grant  awarded by MedImmune 2015 - 2020
  • Private Grant  awarded by MALLINCKRODT, INC. 2019
  • SPRINT-MS: A Randomized Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Activity of Ibudilast (MN-166) in Subjects with Progressive Multiple Sclerosis (NN 102)  awarded by MASSACHUSETTS GENERAL HOSPITAL 2014 - 2018
  • Private Grant  awarded by Teva Pharmaceuticals 2017
  • Private Grant  awarded by BIOGEN IDEC, INC. 2007 - 2015
  • Private Grant  awarded by BIOGEN IDEC, INC. 2010 - 2015
  • Private Grant  awarded by ONO PHARMACEUTICAL COMPANY LTD 2010 - 2014
  • MS Clinical Care Physician Fellowship  awarded by National Multiple Sclerosis Society 2013 - 2014
  • Private Grant  awarded by Genentech 2012 - 2013
  • Private Grant  awarded by Bayer HealthCare 2010 - 2013
  • Private Grant  awarded by ELI LILLY AND COMPANY 2009 - 2013
  • A Multi-Center, Double-Blind, Randomized Study Comparing the Combined Use of Interferon Beta-1a and Glaltiramer Acetate to Either Agent Alone in Patients with Relapsing Remitting multiple Sclerosis (CombiRx-PhaseIII)  awarded by Mount Sinai School of Medicine 2004 - 2012
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION 2006 - 2012
  • Private Grant  awarded by EMD SERONO 2011 - 2012
  • Private Grant  awarded by Bayer HealthCare 2007 - 2011
  • Private Grant  awarded by Bayer HealthCare 2007 - 2011
  • A Study to Evaluate the Factors Influencing Decisions to Change Immunomodulatory Treatment in Patients with Multiple Sclerosis  awarded by CONSORTIUM OF MULTIPLE SCLEROSIS CENTERS 2010 - 2011
  • Private Grant  awarded by EMD SERONO 2006 - 2011
  • Investigator On

  • A Pragmatic Trial to Evaluate the Intermediate-Term Effects of Early, Aggressive Versus Escalation Therapy in People with Multiple Sclerosis (Traditional versus Early Agressive Therapy for Multiple Sclerosis (TREAT-MS) Trial  awarded by Johns Hopkins University 2018 - 2024
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION 2013 - 2023
  • Investigating the Impact of Cognition on Capacity in Multiple Sclerosis  awarded by National Institute of Child Health and Human Development/NIH/DHHS 2018 - 2023
  • Network of Excellence in Neuroscience Clinical Trials (NEXT)  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2018 - 2023
  • Private Grant  awarded by CHUGAI PHARMACEUTICAL COMPANY LTD 2015 - 2021
  • Private Grant  awarded by Genzyme Corporation 2016 - 2021
  • A Phase II/III Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of 2 Potential Disease Modifying Therapies in Individuals at Risk for and with Dominantly Inherited Alzheimer’s Disease  awarded by Washington University 2013 - 2020
  • Private Grant  awarded by BIOGEN, INC. 2018 - 2020
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY 2016 - 2020
  • Lipoic Acid for the Treatment of Progressive Multiple Sclerosis  awarded by Oregon Health & Science University 2017 - 2019
  • The Frontotemporal Lobar Degeneration Clinical Research Consortium  awarded by University of California, San Francisco 2016 - 2019
  • Multiple Sclerosis Clinical Care Physician Fellowship Program  awarded by National Multiple Sclerosis Society 2018 - 2019
  • The Neurodevelopmental Influence of Pediatric Versus Adult Onset MS on Cognition  awarded by NEW YORK UNIVERSITY SCHOOL OF MEDICINE 2016 - 2019
  • Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease(A4 Study)  awarded by University of Southern California 2016 - 2018
  • Causes, Treatment, and Prevention of Corticobasal Degeneration  awarded by University of California, San Francisco 2014 - 2018
  • Network of Excellence in Neuroscience Clinical Trials (NEXT)  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2011 - 2018
  • Alzheimer's Disease Cooperative Study - A4 Study  awarded by University of Southern California 2017 - 2018
  • Tau PET Imaging for the USC Alzheimer's Therapeutic Research Institute (USC ATRI) A4 Trial (“A4 TAU”)  awarded by University of Southern California 2017
  • Advancing Research and Treatment for Frontotemporal Lobar Degeneration [ARTFL]: Research Project 1 & 2  awarded by University of California, San Francisco 2015 - 2017
  • UAB Research and Education Program in Neurology, Neurosurgery, and Neuropathology  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2012 - 2017
  • Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)  awarded by University of Southern California 2016 - 2017
  • Alzheimer's Disease Cooperative Study - A4 Study  awarded by University of Southern California 2015 - 2017
  • CREST: Carotid Revascularization Endarterectomy vs. Stent Trial  awarded by Rutgers, the State University of New Jersey 2010 - 2016
  • Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study: A Companion Observational Study to Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Trial  awarded by University of Southern California 2015 - 2016
  • Private Grant  awarded by C2N DIAGNOSTICS, LLC 2015 - 2016
  • Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)  awarded by University of California, San Diego 2012 - 2016
  • Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - The LEARN Study A Companion Observational Study to Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Trial  awarded by University of California, San Diego 2015
  • Private Grant  awarded by ALLERGAN, INC. 2012 - 2015
  • Alzheimer's Disease Cooperative Study  awarded by University of California, San Diego 2013 - 2015
  • Private Grant  awarded by MALLINCKRODT, INC. 2015
  • Rehabilitating Extremity Use after Multiple Sclerosis  awarded by National Multiple Sclerosis Society 2009 - 2014
  • A Double-Blind, Placebo-Controlled (Sham Surgery), Randomized, Multicenter Study Evaluating CERE-110 Gene Delivery in Subjects with Mild to Moderate Alzheimer's Disease (CERE 110-3)  awarded by University of California, San Diego 2011 - 2013
  • Education And Training

  • Master of Public Health in Epidemiology, University of Alabama at Birmingham 2001
  • Doctor of Medicine, 1990
  • Southern Illinois University SOM, Internship 1993
  • Southern Illinois University SOM, Residency 1997
  • UAB Hospital, Postdoctoral Fellowship 1999
  • Full Name

  • Khurram Bashir